Veloxa Chewable Beef Flavoured Tablets for Dogs

Veloxa Chewable Beef Flavoured Tablets for Dogs

In stock

  • Effective against the four most common internal worms in dogs: tapeworms, roundworm, hookworm and whipworm
  • Enhanced with praziquantel which helps your pet's immune system fight against parasites
  • Can be fed easily without having the need to mix with food
  • Recommended for use in dogs with less than 17.5 bodyweight
  • Fortified with febantel, an anthelmintic commonly taken orally
Product Name Price Qty
Veloxa Chewable Beef Flavoured Tablets for Dogs - 2 Pack
Veloxa Chewable Beef Flavoured Tablets for Dogs - 4 Pack
Veloxa Chewable Beef Flavoured Tablets for Dogs - 6 Pack
Veloxa Chewable Beef Flavoured Tablets for Dogs - 8 Pack


Please note that due to regulatory law and the legal category of this medicine, returns will not be accepted.

Veloxa Beef flavoured Chewable Worming Tablets for Dogs is an effective treatment against the four most common internal worms in dogs: tapeworms, roundworms, hookworms and whipworms. Your pup can easily swallow this remedy as it comes in a tasty beef flavoured chewable tablet. It can be fed easily without having the need to mix with your pet's food. Veloxa Beef flavoured Chewable Worming Tablets for Dogs also contains febantel and praziquantel, common anthelmintics.


Brand Veloxa


At Petwell we offer 2 types of products that have different shipping rates:

Regular Products

  • Orders over £29 of regular products receive FREE SHIPPING (*3-5 Days)
  • Orders under £29 incur a £2.99 shipping charge for Standard Shipping (*3-5 days)
  • Express Tracked (*1-3 Days) and Premium Tracked (*1 Day) shipping options available at checkout.
  • "Regular" products are highlighted blue on the basket page


Shipping Included Products

  • No shipping charges at checkout.
  • Not counted towards free shipping for "regular" products over £29
  • "Shipping included" products are easy to spot, they have an orange ‘Shipping Included’ sticker placed on the top of the product and are highlighted orange on the basket page.
  • Sent separately via Standard (*3-5 Day) shipping service


 *Estimated delivery time from when the order is despatched (orders are usually despatched within 1-2 working days)




Highlands & Islands

Deliveries to the following locations and postcodes on orders over 2Kg incur a £4.99 courier charge. (there is no extra charge for UK mainland orders over 2Kg)

Premium tracked (1 day) delivery is not available

Channel Islands - GY, JE
Isle of Man – IM
Isles of Scilly – TR
Isle of Wight – PO
Northern Ireland - BT
Northern Scotland - AB, FK, IV, KW, PA, PH
Scottish Offshore Islands - HS, IV, KA, KW, PA, PH, ZE



Unfortunately, we cannot currently deliver outside of the British Isles


Veloxa and Veloxa XL Chewable Tablets for Dogs
Therapeutic indication:Pharmaceuticals: Endoparasiticides: Anthelmintics for dogs, Tapeworm products
Active ingredient:Febantel, Praziquantel, Pyrantel Embonate
Product:Veloxa Chewable Tablets for Dogs
Veloxa XL Chewable Tablets for Dogs
Product index:Veloxa
Qualitative and quantitative composition
Each Veloxa chewable tablet contains:
Active substances
Febantel 150 mg
Pyrantel 50 mg (corresponding to Pyrantel embonate 144 mg)
Praziquantel 50 mg
Each Veloxa XL chewable tablet contains:
Active substances
Febantel 525 mg
Pyrantel 175 mg (corresponding to Pyrantel embonate 504 mg)
Praziquantel 175 mg
For the full list of excipients, see below.
Pharmaceutical form
Chewable tablet.
Brownish, oval, divisible tablet. It can be divided into equal parts.
Clinical particulars
Target species
Indications for use
Anthelmintic for treatment of mixed infections by the following roundworms and tapeworms in dogs and puppies:
Ascarids: Toxocara canisToxascaris leonina (adult and late immature forms)
Hookworms: Uncinaria stenocephalaAncylostoma caninum (adults)
Whipworms: Trichuris vulpis (adults)
Tapeworms: Echinococcus spp., Taenia spp. and Dipylidium caninum (adult and immature forms).
Do not use in animals with a known hypersensitivity to any of the active substances or the excipients. Please also see 'Use during pregnancy, lactation or lay' section and 'Interactions' section.
Special warnings for each target species
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.
Fleas serve as intermediate hosts for one common type of tapeworm - Dipylidium caninum. Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc. is undertaken.
Special precautions for use in animals
Veloxa is recommended for use in dogs less than 17.5 kg bodyweight. Veloxa XL is recommended for use in dogs over 17.5 kg bodyweight.
Tapeworm infestation is unlikely in pups less than 6 weeks of age. The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of animals. To minimise the risk of re-infestation and new infestation, excreta should be collected and properly disposed of for 24 hours following treatment.
Special precautions to be taken by the person administering the medicinal product to animals
In the interests of good hygiene, persons administering the chewable tablet directly to a dog or by adding it to the dog's food, should wash their hands afterwards. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Other precaution
Since it contains praziquantel, the product is effective against Echinococcus spp. which do not occur in all EU member states but are becoming more common in some. Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.
Adverse reactions
In very rare cases (less than 1 animal in 10,000 animals, including isolated reports) transient, mild gastrointestinal signs (e.g. vomiting) may occur.
Use during pregnancy, lactation or lay
Teratogenic effects attributed to high doses of febantel have been reported in sheep and rats. No studies have been performed in dogs during early pregnancy. Use of the product during pregnancy should be in accordance with a benefit/risk assessment by the responsible veterinarian. It is recommended that the product is not used in dogs during the first 4 weeks of pregnancy. Do not exceed the stated dose when treating pregnant bitches.
The chewable tablets may be used during lactation.
Do not use simultaneously with piperazine as the anthelmintic effects of pyrantel and piperazine may be antagonised.
Concurrent use with other cholinergic compounds can lead to toxicity.
Plasma concentrations of praziquantel may be decreased by concomitant administration with drugs that increase the activity of cytochrome P-450 enzymes (e.g. dexamethasone, phenobarbital).
Amounts to be administered and administration route
For oral administration only.
Veloxa Dosage
1 chewable tablet per 10 kg bodyweight (15 mg febantel, 5 mg pyrantel (as embonate) and 5 mg praziquantel/kg bodyweight).
Weight (kg)
Number of chewable tablets
2.5 - 5
> 5 - 10
> 10 - 15
> 15 - 20
> 20- 25
> 25 - 30
For dogs weighing more than 30 kg (i.e. >30 kg) the XL strength should be used. To ensure administration of a correct dose, body weight should be determined as accurately as possible.
Veloxa XL Dosage
1 chewable tablet per 35 kg bodyweight (15 mg febantel, 5 mg pyrantel (as embonate) and 5 mg praziquantel/kg body weight).
Weight (kg)
Number of chewable tablets
>17.5 - 35
>35 - 52.5
>52.5 - 70
Do not use for treatment of dogs weighing less than 17.5 kg (i.e. <17.5 kg). To ensure administration of a correct dose, body weight should be determined as accurately as possible.
The chewable tablets can be given directly to the dog or disguised in food. No starvation is needed before or after treatment. Due to a lipid-coating of praziquantel and added flavour, the chewable tablets are taken by most dogs voluntarily.
Duration of treatment
Not for use in dogs weighing less than 2 kg. A single dose shall be used. If there is a risk of re-infestation, the advice of a veterinarian should be sought regarding the need for and the frequency of repeat administration.
In safety studies, a single dose of 5 times the recommended dose or greater gave rise to occasional vomiting.
Pharmacological particulars
Pharmacodynamic properties
In this fixed combination product pyrantel and febantel act against all relevant nematodes (ascarids, hookworms and whipworms) in dogs. In particular, the activity spectrum covers Toxocara canisToxascaris leoninaUncinaria stenocephalaAncylostoma caninum and Trichuris vulpis. This combination shows synergistic activity in the case of hookworms and febantel is effective against T. vulpis. The spectrum of activity of praziquantel covers all important cestode species in dogs, in particular all Taenia spp, Dipylidium caninumEchinococcus granulosus and Echinococcus multilocularis. Praziquantel acts against adult and immature forms of these parasites.
Praziquantel is very rapidly absorbed and distributed throughout the parasite. Both in vitro and in vivo studies have shown that praziquantel causes severe damage to the parasite integument, resulting in contraction and paralysis. There is an almost instantaneous tetanic contraction of the parasite musculature and a rapid vacuolisation of the syncytial tegument. This rapid contraction has been explained by changes in divalent cation fluxes, especially calcium.
Pyrantel acts as a cholinergic agonist. Its mode of action is to stimulate nicotinic cholinergic receptors of the parasite, induce spastic paralysis and thereby allow removal from the gastrointestinal system by peristalsis.
Within the mammalian system febantel undergoes ring closure forming fenbendazole and oxfendazole. It is these chemical entities which exert the anthelmintic effect by inhibition of tubulin polymerisation. Formation of microtubules is thereby prevented, resulting in disruption to structures vital to the normal functioning of the helminth. Glucose uptake, in particular, is affected, leading to depletion in cell ATP. The parasite dies upon exhaustion of its energy reserves, which occurs 2-3 days later.
Pharmacokinetic properties
After oral administration, praziquantel is almost completely absorbed from the intestinal tract. After absorption, the drug is widely distributed in the organism, metabolised into inactive forms in the liver and secreted in bile. It is excreted within 24 hours to more than 95% of the administered dosage.
The embonate salt of pyrantel has low aqueous solubility, an attribute that reduces absorption from the gut and allows the drug to reach and be effective against parasites in the large intestine. Following absorption, pyrantel embonate is quickly and almost completely metabolised into inactive components which are rapidly excreted in the urine.
Febantel is an inactive pro-drug which is absorbed and then metabolised relatively rapidly to a number of metabolites, including fenbendazole and oxfendazole, which have anthelmintic activity.
Following the single oral administration of this veterinary medicinal product the maximum plasma concentrations of praziquantel, pyrantel, fenbendazole and oxfendazole were found 327, 81, 128 and 165 ng/ml and were obtained after 2.2, 4.5, 5.2 and 6.3 hours.
Pharmaceutical particulars
Cetyl palmitate, Starch (pregelatinised), Sodium starch glycolate (type A), Colloidal anhydrous silica, Magnesium stearate, Artificial beef flavour.
Major incompatibilities
Not applicable.
Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf-life of half tablets: 2 days
Special precautions for storage
This medicinal product does not require any special storage conditions.
Keep the blister in the outer carton. Each time an unused half tablet is stored it should be returned to the open blister space and the blister inserted back into the outer carton.
Immediate packaging
PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 (Veloxa strength only) chewable tablets.
Veloxa packs: 2, 4, 8, and 104 chewable tablets.
Veloxa XL packs: 2, 4, 8, 48 and 96 chewable tablets.
Not all pack sizes may be marketed.
Any unused veterinary medicinal products or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
Lavet Pharmaceuticals Ltd
1161 Budapest
Ottó u. 14
Marketing Authorisation Number
Vm 32823/4010
Legal category
Legal category:NFA-VPS



Please wait...

{{if product.parent_product}}{{var }}{{else}}{{var}}{{/if}} was added to your basket

Continue Shopping View Basket & Checkout

Suggested Products

{{var}} has been removed from your basket

Continue Shopping